A main purpose of the present disclosure is to provide a formulation containing a polymer and having excellent stability in terms of at least one type of drug selected from the group consisting of cetuximab, bevacizumab, faricimab, ranibizumab, and brolucizumab. The inventors of the present invention found that it is possible to provide a formulation which contains a polymer and has excellent stability in terms of at least one type of drug selected from the group consisting of cetuximab, bevacizumab, faricimab, ranibizumab, and brolucizumab by providing a microcapsule encapsulating said drug, wherein the microcapsule contains a polymer having a chemical structure in which a branched polyalkylene glycol having 3 to 10 terminal hydroxy groups per molecule and a polyhydroxyalkanoic acid are bonded, and in the polymer, the number of units of the polyhydroxyalkanoic acid monomer per single polyhydroxyalkanoic acid chain is 50 to 230.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
The main purpose of the present disclosure is to provide a preparation which contains a polymer and in which a water-soluble substance exhibits excellent stability. The inventors of the present invention found that a preparation in which a water-soluble substance exhibits excellent stability can be provided by a microcapsule encapsulating a water-soluble substance, said microcapsule comprising the water-soluble substance and a polymer that has a chemical structure in which polyalkylene glycol and polyhydroxyalkanoic acid are bonded, wherein the total volume of an aqueous phase in a W/O emulsion prepared from the polymer by the following method is 0.025-0.25 cm3/g, as measured by differential scanning calorimetry (heating method). W/O emulsion preparation method: 50 mg of the polymer is dissolved in 500 μL of a 0.5w/v% sorbitan monooleate/dichloromethane solution, 100 μL of water is added, and then a resultant solution is irradiated with ultrasonic waves to prepare the W/O emulsion.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 9/52 - Préparations en capsules, p. ex. de gélatine, de chocolat du type à libération prolongée ou discontinue
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
G01N 15/00 - Recherche de caractéristiques de particulesRecherche de la perméabilité, du volume des pores ou de l'aire superficielle effective de matériaux poreux
05 - Produits pharmaceutiques, vétérinaires et hygièniques
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Eye drops; eye drops for animals; medicated shampoos for
pets; veterinary preparations; pharmaceutical preparations;
greases for medical purposes; drug delivery agents in the
form of edible wafers for wrapping powdered pharmaceuticals;
gauze for dressings; empty capsules for pharmaceuticals;
eyepatches for medical purposes; ear bandages; menstruation
bandages; sanitary tampons; sanitary napkins; sanitary
panties; absorbent cotton; adhesive plasters; bandages for
dressings; liquid bandages; breast-nursing pads; dental
materials; dietary supplements for humans; dietetic
beverages adapted for medical purposes; dietetic foods
adapted for medical purposes; dietary supplements for
animals. Medical care; provision of medical information; physical
examination; dental clinic services; dispensing of
pharmaceuticals; animal breeding; veterinary services;
beauty care services for animals; rental of medical machines
and apparatus.
4.
HETEROCYCLIDENE-ACETAMIDE-DERIVATIVE-CONTAINING COMPOSITION SUBJECTED TO ELECTRON BEAM STERILIZATION TREATMENT
The present disclosure provides an aqueous liquid agent having exceptional stability. The present disclosure provides an aqueous liquid agent containing electron-beam-treated (E)-2-(7-trifluoromethylchroman-4-yldene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmacologically acceptable salt or solvate thereof. In particular, the present disclosure relates to technology for improving the stability of a suspension that contains a heterocyclidene acetamide derivative, and formulation technology based thereupon.
The present disclosure provides a means for improving the ocular tissue transfer and photostability of dexamethasone. In the present disclosure, there can be provided: a pharmaceutical composition or a drug for improving the ocular tissue transfer and photostability of a dexamethasone phosphate ester or a pharmaceutically acceptable salt thereof; or a use of the pharmaceutical composition or the drug. In addition, in the present disclosure, there can be provided: a pharmaceutical composition or a drug, each of which is for treating and/or preventing an eye disease and comprises a dexamethasone phosphate ester or a pharmaceutically acceptable salt thereof and a β-blocker; or a use of the pharmaceutical composition or the drug.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
The purpose of the present invention is to provide a PACAP peptide having improved stability. The present invention is based on the finding that the stability of PACAP is significantly improved by substituting aspartic acid at positions 3 and 8 in the sequence of PACAP with at least one amino acid selected from the group consisting of tetrazole-substituted aspartic acid (Tz), tetrazole-substituted glutamic acid (egTz), tetrazole-substituted homoglutamic acid (nvTz), sulfoxy-substituted aspartic acid (cya), and oxadiazolone-substituted aspartic acid (5Oxa).
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Industrial chemicals; industrial chemicals used as materials
in the manufacture of cosmetics; chemical preparations for
use in the manufacture of cosmetics; collagen used as a raw
ingredient in the manufacture of cosmetics; antioxidants for
use in the manufacture of cosmetics; plant extracts, other
than essential oils, for use in the manufacture of
cosmetics; vitamins for use in the manufacture of cosmetics;
chemical additives for use in the manufacture of cosmetics. Cosmetics; collagen preparations for cosmetic purposes;
cosmetic preparations for skin care; cosmetic preparations
for the care of mouth and teeth; cosmetics for animals; hair
nourishers for cosmetic purposes; soaps and detergents;
non-medicated mouthwashes; non-medicated dentifrices;
perfumery; fragrances and incense; false nails; false
eyelashes; bath preparations, not for medical purposes. Medicines for human purposes; pharmaceutical preparations;
medicated mouth care and treatment preparations; medicated
mouthwashes; medicinal hair growth preparations; medicinal
preparations for stimulating hair growth; bath preparations
for medical purposes.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Chemical preparations for use in industry; chemical preparations for general industrial manufacturing; industrial chemicals used as materials in the manufacture of cosmetics; chemical preparations for use in the manufacture of cosmetics; collagen used as a raw ingredient in the manufacture of cosmetics; antioxidants for use in the manufacture of cosmetics; plant extracts, other than essential oils, for use in the manufacture of cosmetics; vitamins for use in the manufacture of cosmetics; chemical additives for use in the manufacture of cosmetics
The present disclosure provides suspendable ophthalmic solutions with excellent redispersibility. The present disclosure provides an aqueous suspension agent comprising (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, a cellulosic polymer, and a nonionic surfactant.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Pharmaceutical preparations for ophthalmic use; eye drops; contact lens cleaning preparations; solutions for contact lenses; pharmaceutical, veterinary and sanitary preparations for medical purposes; oiled paper for medical purposes; cachets for pharmaceutical purposes; gauze for dressings; empty capsules for pharmaceuticals; eye patches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid dressings; breast-nursing pads; dental materials Finger guards for medical purposes; pacifiers for babies; ice bag pillows for medical purposes; triangular bandages; supportive bandages; surgical catguts; feeding cups for medical purposes; dropping pipettes for medical purposes; teats; medical ice bags; medical ice bag holders; baby bottles; nursing bottles; diagnostic apparatus and instruments; surgical apparatus and instruments; therapeutic apparatus and instruments; medical apparatus and instruments; veterinary apparatus and instruments; auxiliary medical devices and orthodontic apparatus; sanitary masks
The present disclosure provides an eye disease model animal, a method for producing the eye disease model animal, and a method for screening therapeutic agents and/or prophylactic agents for dry eye. One aspect of the present disclosure provides a dry eye model animal that has a characteristic associated with meibomian gland dysfunction. Another aspect of the present disclosure provides a method for producing the dry eye model animal, the method including a step for transplanting cells from an animal that is allogeneic to the dry eye model animal into an animal that has reduced or deficient immune function.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Eye drops; ophthalmological preparations; medical
preparations; oiled paper for medical purposes; adhesive
tapes for medical purposes; drug delivery agents in the form
of edible wafers for wrapping powdered pharmaceuticals;
gauze for dressings; empty capsules for pharmaceuticals;
eyepatches for medical purposes; ear bandages; menstruation
bandages; sanitary tampons; sanitary napkins; sanitary
panties; absorbent wadding; adhesive plasters; bandages for
dressings; liquid bandages; breast-nursing pads; cotton
swabs for medical purposes; dietary supplements for human
beings; dietetic beverages adapted for medical purposes;
dietetic foods adapted for medical purposes; beverages for
babies; food for babies.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Eye drops; ophthalmological preparations; medical
preparations; oiled paper for medical purposes; adhesive
tapes for medical purposes; drug delivery agents in the form
of edible wafers for wrapping powdered pharmaceuticals;
gauze for dressings; empty capsules for pharmaceuticals;
eyepatches for medical purposes; ear bandages; menstruation
bandages; sanitary tampons; sanitary napkins; sanitary
panties; absorbent wadding; adhesive plasters; bandages for
dressings; liquid bandages; breast-nursing pads; cotton
swabs for medical purposes; dietary supplements for human
beings; dietetic beverages adapted for medical purposes;
dietetic foods adapted for medical purposes; beverages for
babies; food for babies.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Eye drops; ophthalmological preparations; medical
preparations; oiled paper for medical purposes; adhesive
tapes for medical purposes; drug delivery agents in the form
of edible wafers for wrapping powdered pharmaceuticals;
gauze for dressings; empty capsules for pharmaceuticals;
eyepatches for medical purposes; ear bandages; menstruation
bandages; sanitary tampons; sanitary napkins; sanitary
panties; absorbent wadding; adhesive plasters; bandages for
dressings; liquid bandages; breast-nursing pads; cotton
swabs for medical purposes; dietary supplements for human
beings; dietetic beverages adapted for medical purposes;
dietetic foods adapted for medical purposes; beverages for
babies; food for babies.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Eye drops; ophthalmological preparations; medical
preparations; oiled paper for medical purposes; adhesive
tapes for medical purposes; drug delivery agents in the form
of edible wafers for wrapping powdered pharmaceuticals;
gauze for dressings; empty capsules for pharmaceuticals;
eyepatches for medical purposes; ear bandages; menstruation
bandages; sanitary tampons; sanitary napkins; sanitary
panties; absorbent wadding; adhesive plasters; bandages for
dressings; liquid bandages; breast-nursing pads; cotton
swabs for medical purposes; dietary supplements for human
beings; dietetic beverages adapted for medical purposes;
dietetic foods adapted for medical purposes; beverages for
babies; food for babies.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Eye drops; ophthalmological preparations; medical
preparations; oiled paper for medical purposes; adhesive
tapes for medical purposes; drug delivery agents in the form
of edible wafers for wrapping powdered pharmaceuticals;
gauze for dressings; empty capsules for pharmaceuticals;
eyepatches for medical purposes; ear bandages; menstruation
bandages; sanitary tampons; sanitary napkins; sanitary
panties; absorbent wadding; adhesive plasters; bandages for
dressings; liquid bandages; breast-nursing pads; cotton
swabs for medical purposes; dietary supplements for human
beings; dietetic beverages adapted for medical purposes;
dietetic foods adapted for medical purposes; beverages for
babies; food for babies.
A fluorescent probe that detects calpain enzyme activity with high sensitivity, wherein, enzymatic reactivity with a calpain is improved by bonding an amide group having α-carbon, which is bonded to an oxygen atom, to the N-terminal of a peptide chain. A fluorescent probe detects calpain activity with higher sensitivity because the probe is improved in reactivity with a calpain as compared to a HMRG fluorescent probe that has heretofore been reported. Specifically, the fluorescent probe relates to a compound represented by the following general formula (I) or a salt thereof.
A fluorescent probe that detects calpain enzyme activity with high sensitivity, wherein, enzymatic reactivity with a calpain is improved by bonding an amide group having α-carbon, which is bonded to an oxygen atom, to the N-terminal of a peptide chain. A fluorescent probe detects calpain activity with higher sensitivity because the probe is improved in reactivity with a calpain as compared to a HMRG fluorescent probe that has heretofore been reported. Specifically, the fluorescent probe relates to a compound represented by the following general formula (I) or a salt thereof.
C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The present disclosure provides a technology for maintaining, improving and increasing etc. capability for coordinated action of eyes and body. The inventors of the present invention achieved the technology of the present disclosure based on the finding that capability for coordinated action of eyes and body can be maintained, improved and increased etc. by administration of an oral composition containing xanthophyll.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Eye drops; ophthalmological preparations; pharmaceutical products and preparations for ophthalmological use; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; allergy capsules; capsules sold empty for pharmaceuticals; gelatin capsules, empty, for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; sanitary tampons; sanitary napkins; sanitary panties; absorbent wadding for medical purposes; adhesive plasters for medical purposes; bandages for dressings; liquid bandages for skin wounds; liquid bandage sprays; breast-nursing pads; cotton swabs for medical purposes; dietary supplements for human beings; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies, namely, liquid formula for babies, powdered milk for babies; food for babies
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Eye drops; ophthalmological preparations; pharmaceutical products and preparations for ophthalmological use; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; allergy capsules; capsules sold empty for pharmaceuticals; gelatin capsules, empty, for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; sanitary tampons; sanitary napkins; sanitary panties; absorbent wadding for medical purposes; adhesive plasters for medical purposes; bandages for dressings; liquid bandages for skin wounds; Liquid bandage sprays; breast-nursing pads; cotton swabs for medical purposes; dietary supplements for human beings; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies, namely, liquid formula for babies, powdered milk for babies; food for babies
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Eye drops; ophthalmological preparations; pharmaceutical products and preparations for ophthalmological use; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; allergy capsules; capsules sold empty for pharmaceuticals; gelatin capsules, empty, for pharmaceuticals; eye patches for medical purposes; ear bandages; menstruation bandages; sanitary tampons; sanitary napkins; sanitary panties; absorbent wadding for medical purposes; adhesive plasters for medical purposes; bandages for dressings; liquid bandages for skin wounds; liquid bandage sprays; breast-nursing pads; cotton swabs for medical purposes; dietary supplements for human beings; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies, namely, liquid formula for babies, powdered milk for babies; food for babies
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Eye drops; ophthalmological preparations; pharmaceutical products and preparations for ophthalmological use; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; allergy capsules; capsules sold empty for pharmaceuticals; gelatin capsules, empty, for pharmaceuticals; eye patches for medical purposes; ear bandages; menstruation bandages; sanitary tampons; sanitary napkins; sanitary panties; absorbent wadding for medical purposes; adhesive plasters for medical purposes; bandages for dressings; liquid bandages for skin wounds; liquid bandage sprays; breast-nursing pads; cotton swabs for medical purposes; dietary supplements for human beings; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies, namely, liquid formula for babies, powdered milk for babies; food for babies.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Eye drops; ophthalmological preparations; pharmaceutical products and preparations for ophthalmological use; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; allergy capsules; capsules sold empty for pharmaceuticals; gelatin capsules, empty, for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; sanitary tampons; sanitary napkins; sanitary panties; absorbent wadding for medical purposes; adhesive plasters for medical purposes; bandages for dressings; liquid bandages for skin wounds; liquid bandage sprays; breast-nursing pads; cotton swabs for medical purposes; dietary supplements for human beings; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies, namely, liquid formula for babies, powdered milk for babies; food for babies
NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT (Japon)
SENJU PHARMACEUTICAL CO., LTD. (Japon)
Inventeur(s)
Azuma Noriyuki
Fukiage Chiho
Kishimoto Yayoi
Kobayashi Momoko
Abrégé
The present invention relates to: a composition for improving retinal function, the composition comprising at least one protein selected from the group consisting of chemerin, NPC2, and SMOC1; and a method for producing retinal ganglion cells, the method comprising culturing retinal progenitor cells in the presence of at least one protein selected from the group consisting of chemerin, NPC2, and SMOC1.
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 35/30 - NerfsCerveauYeuxCellules cornéennesLiquide céphalorachidienCellules souches neuronalesCellules précurseurs neuronalesCellules glialesOligodendrocytesCellules de SchwannAstrogliesAstrocytesPlexus choroïdeTissu de moelle épinière
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The present disclosure provides suspendable ophthalmic solutions with excellent redispersibility. The present disclosure provides an aqueous suspension agent comprising (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, a cellulosic polymer, and a nonionic surfactant.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
Compounds represented by formula (I), compounds of the less-polar group of two groups of diastereomers in which the carbon atom indicated by * in formula (II) is an asymmetric carbon atom, salts of the compounds, and solvates of the compounds or salts. The compounds have Nrf2 activating action.
C07D 419/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote, d'oxygène et de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
The present disclosure provides a suspension ophthalmic solution having exceptional re-dispersibility. More specifically, the present disclosure provides an aqueous suspension containing heat-treated (E)-2-(7-trifluoromethylchroman-4-yldene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmacologically acceptable salt or solvate thereof. In particular, the present disclosure relates to technology for improving the re-dispersibility of a suspension that contains a heterocyclidene acetamide derivative or to formulation technology based thereupon.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
The present disclosure provides a suspension-type ophthalmic solution having excellent re-dispersibility. More specifically, the present disclosure provides a water-based suspension preparation containing a first component and a second component, in which the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, and the second component comprises at least one component selected from the group consisting of diquafosol, ciclosporin, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone and pharmaceutically acceptable salts or solvates thereof.
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
A61K 31/57 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone
A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
The present invention aims to develop a method for treating COVID-19 caused by SARS-CoV-2 or a mutant strain thereof, and provides an agent for preventing and/or treating COVID-19 caused by SARS-CoV-2 or a mutant strain thereof, the agent comprising a specific compound.
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japon)
THE DOSHISHA (Japon)
SENJU PHARMACEUTICAL CO., LTD. (Japon)
Inventeur(s)
Koizumi, Noriko
Okumura, Naoki
Kinoshita, Shigeru
Abrégé
The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/4725 - Isoquinoléines non condensées, p. ex. papavérine contenant d'autres hétérocycles
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 31/4402 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 2, p. ex. phéniramine, bisacodyl
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.
A bodily fluid collection device includes a needle part having a needle tube with a needle tip, and a capillary removably connected to a base end part of the needle tube in a longitudinal direction thereof on a side opposite to the needle tip. A method for collecting a bodily fluid using the bodily fluid collection device, and a method for collecting an aqueous humor using the bodily fluid collection device are also disclosed.
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
A61B 5/15 - Dispositifs de prélèvement d'échantillons de sang
The present disclosure provides the use of a polyether compound. In one embodiment, the present disclosure relates to improvement of the stability of a polyether compound that uses a polyether compound and improvement of the solubility of a sparingly soluble compound. In one embodiment, the present disclosure relates to a composition that includes a chelating compound, the composition being for stabilizing a polyether compound. In one embodiment, the present disclosure relates to a composition for improving the solubility of a sparingly soluble compound, the composition including at least one of a hydrophobic polyoxyaliphatic moiety-containing polyether compound and a hydrating compound, by combining a hydrophobic polyoxyaliphatic moiety-containing polyether compound and a hydrating compound. In one embodiment, regarding the present disclosure, regarding the polyether compound, the polyether compound includes a poloxamer and polyethylene glycol.
A compound having Nrf2-activating action is provided. The compound is represented by formula (I), a salt of the compound, or a solvate of the compound or salt:
A compound having Nrf2-activating action is provided. The compound is represented by formula (I), a salt of the compound, or a solvate of the compound or salt:
A compound having Nrf2-activating action is provided. The compound is represented by formula (I), a salt of the compound, or a solvate of the compound or salt:
wherein R1a and R1b are identical or different and represent a hydrogen atom, an alkyl group, or a halogen atom; R2 represents an optionally substituted group derived from a heterocycle, and the heterocycle represents thiophene, furan, pyrrole, thiazole, or a fused ring including any of these heterocycles; R4 and R5 are identical or different and represent a hydrogen atom or an optionally substituted alkyl group, or R4 and R5 bind with each other to form —NH—CH—N—; R6 represents an optionally substituted alkyl group; A1, A2, A3, and A4 are identical or different and represent CH or N wherein the number of N is 1 or less; and Z represents a hydrogen atom or a halogen atom.
C07D 291/08 - Composés hétérocycliques contenant des cycles comportant des atomes d'azote, d'oxygène et de soufre comme uniques hétéro-atomes du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 419/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote, d'oxygène et de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 419/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote, d'oxygène et de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 409/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
The purpose of the present invention is to provide a fluorescent probe that detects calpain enzymatic activity with high sensitivity. This invention increases the enzymatic reactivity with calpain by bonding an amino group which has an α carbon bonded to an oxygen atom, to the N terminal of a peptide chain. In comparison with conventionally reported HMRG fluorescent probes, this probe has improved reactivity with calpain, so a fluorescent probe is provided which that detects calpain activity with higher sensitivity. Specifically, the present invention relates to the compound represented in general formula (I) or a salt thereof.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
45.
NOVEL USE OF NICOTINAMIDE MONONUCLEOTIDE (NMN) AND NICOTINAMIDE RIBOSIDE (NR)
The present disclosure provides a novel use of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). The present disclosure provides a composition that includes nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) for use in treating or preventing diseases, disorders, or symptoms related to activation of Hsd3b6 or a homolog thereof, and a method using the composition. In one embodiment, a composition including NMN or NR for use in improving the function of meibomian glands, and a method using the composition are provided.
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
Provided are suspension eye drops having superior re-dispersibility. The present disclosure provides an aqueous suspension agent that contains (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalene-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, a cellulose-based polymer, and a nonionic surfactant.
Kyoto Prefectural Public University Corporation (Japon)
The Doshisha (Japon)
Senju Pharmaceutical Co., Ltd. (Japon)
Inventeur(s)
Koizumi, Noriko
Okumura, Naoki
Kinoshita, Shigeru
Abrégé
The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGFβ-signal inhibitor. As a preferred TGFβ-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
The present disclosure provides a marker that shows a relationship with changes in the nerve density and morphology in the cornea. In one aspect, the present invention provides a marker for neuropathy in the eye, the expression of which changes in correlation with morphological parameters of the nerves in the eye. In some embodiments, the parameter may include at least one parameter selected from the group consisting of CNBD, CTBD, CNFD, CNFL, and tortuosity. In a particular embodiment, the parameter may include at least one parameter selected from CNBD and CTBD.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The present invention addresses the problem of providing a compound having Nrf2-activation action. Provided are: compounds represented by general formula (I), or compounds of the lower-polarity group among two groups of diastereomers in which the carbon atom indicated by * in general formula (II) is an asymmetric carbon atom; salts of these; and solvates of these.
C07D 419/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote, d'oxygène et de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
A61K 31/554 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. clothiapine, diltiazem
The purpose of the present invention is to provide a composition for preventing or treating neurotrophic keratitis. It is found that PACAP peptide exerts an effect to prevent corneal damages in a neurotrophic keratitis model and can promote neurite extension in a cultured nerve cell model. Furthermore, stability can be significantly increased by substituting a carboxyl group in an aspartic acid residue located at position-3 and/or position-8 in the sequence for PACAP by tetrazole. Provided are: a composition for preventing or treating neurotrophic keratitis, which contains PACAP peptide or stabilized PACAP peptide, and a neurite extension promoting agent.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention relates to a retinal ganglion cell death suppressor comprising a BMPR signal transduction inhibitor, a drug comprising a BMPR signal transduction inhibitor for protecting retinal neurons, and a pharmaceutical composition using these for preventing or treating a disease involving retinal ganglion cell death, such as glaucoma, diabetic retinopathy and retinal vascular occlusion.
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The purpose of the present invention is to provide a liquid preparation for ophthalmic use which comprises brimonidine or a salt thereof. On the basis of the finding that a liquid preparation for ophthalmic use which contains brimonidine at a low concentration and to which vitamins are added has good transferability to the conjunctiva, provided is a liquid preparation for ophthalmic use which contains brimonidine at a low concentration and vitamins. Brimonidine at a low concentration is highly compatible with vitamins and stabilizes the vitamins which frequently cause reduction in the content thereof.
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
Provided are a bodily fluid collecting device that is capable of collecting a fixed quantity of bodily fluid while minimizing biological damage, as well as a bodily fluid collecting method and urine collecting method that use said device. The bodily fluid collecting device 1 comprises: a needle part 2 having a needle tube 3 on which is formed a needle tip 32; and a capillary 5 removably connected to a base end section 33 that is on the side opposite to the needle tip 32 in the longitudinal direction of the needle tube 3.
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
A61B 3/10 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
The objective of the present invention is to provide a hydrogel having a favorable shape stability not only after releasing an anionic drug contained but also in the process of releasing such an anionic drug, compared with the conventional techniques; and an anionic drug-containing ophthalmic device obtained by applying the hydrogel. The objective can be achieved by an anionic drug-containing ophthalmic device comprising: (1) an anionic drug; and (2) a copolymer which comprises a cationic monomer and a monomer capable of copolymerizing with the cationic monomer, wherein the cationic monomer comprises, as a structural component, a condensation product of (meth)acrylic acid with an aminoalkyl quaternary ammonium compound having a substituted or unsubstituted aralkyl group, or a salt of the condensation product; and the like.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61F 9/007 - Procédés ou dispositifs pour la chirurgie de l'œil
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61L 27/16 - Matériaux macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
The purpose of the present invention is to provide technology relating to a pharmaceutical product that includes an aqueous liquid containing chlorous acid and/or a salt thereof and boric acid and/or a salt thereof, and can suppress a decrease in the content of the chlorous acid and/or the salt thereof. A pharmaceutical product formed by accommodating, in a container subjected to a gas sterilization treatment, an aqueous liquid that includes chlorous acid and/or a salt thereof, boric acid and/or a salt thereof, and brimonidine and/or a salt thereof.
The present disclosure provides the use of a polyether compound. In one embodiment, the present disclosure relates to improvement of the stability of a polyether compound that uses a polyether compound and improvement of the solubility of a sparingly soluble compound. In one embodiment, the present disclosure relates to a composition that includes a chelating compound, the composition being for stabilizing a polyether compound. In one embodiment, the present disclosure relates to a composition for improving the solubility of a sparingly soluble compound, the composition including at least one of a hydrophobic polyoxyaliphatic moiety-containing polyether compound and a hydrating compound, by combining a hydrophobic polyoxyaliphatic moiety-containing polyether compound and a hydrating compound. In one embodiment, regarding the present disclosure, regarding the polyether compound, the polyether compound includes a poloxamer and polyethylene glycol.
A61K 47/46 - Ingrédients de constitution indéterminée ou leurs produits de réaction, p. ex. peau, os, lait, fibre de coton, coquille d’œuf, fiel de bœuf ou extraits de plante
A purpose of the present invention is to provide a technology pertaining to an ophthalmological pharmaceutical product wherein an aqueous liquid agent that includes brimonidine and/or a salt thereof is housed in a colorless, transparent container. This pharmaceutical product is obtained by housing, in a colorless, transparent polyethylene container, an aqueous liquid agent that includes brimonidine and/or a salt thereof as well as a metal chloride.
The purpose of the present invention is to provide a pharmaceutical composition having a high storage stability. This pharmaceutical composition comprises 0.0005-0.05 w/v% inclusive of glucose, a nonionic surfactant and an alkyldiaminoethylglycine hydrochloride.
A61K 31/185 - AcidesLeurs anhydrides, halogénures ou sels, p. ex. acides du soufre, acides imidiques, hydrazoniques ou hydroximiques
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
The purpose of the present invention is to provide a medicinal composition for soft contact lenses which contains an alkyldiaminoethylglycine inhibited from being adsorbed onto soft contact lenses. This medicinal composition for soft contact lenses contains 0.001-0.0045 w/v% alkyldiaminoethylglycine hydrochloride, menthol, and taurine.
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
The purpose of the present invention is to provide a pharmaceutical composition for a soft contact lens, in which the adsorption of alkyldiaminoethylglycine onto the soft contact lens is suppressed. The pharmaceutical composition for a soft contact lens according to the present invention contains: 0.001-0.008 w/v% of an alkyldiaminoethylglycine hydrochloride; and a metal chloride.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
This disclosure provides a means for treating dry eye. This disclosure can provide: a composition for treating dry eye; and a use thereof. The composition includes (E) -2-(7-trifluoromethyl-chroman-4-yllidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalene-1-yl)acetamide, a pharmaceutically acceptable salt thereof, or a solvate thereof. This disclosure can provide: a composition for treating dry eye; and a use thereof. The composition includes a Vi/Vc zone inhibitor.
The purpose of the present invention is to provide a formulation technique pertaining to an aqueous liquid formulation that contains brimonidine and/or a salt thereof. This aqueous liquid formulation contains brimonidine and/or a salt thereof, a buffering agent, and a metal chloride, is capable of inhibiting the adsorption of brimonidine and/or a salt thereof to a filter when passed through the filter, and is capable of suppressing the reduction of the contained amount of brimonidine and/or a salt thereof in the aqueous liquid formulation even when contained in a container with a filter or when subjected to a sterilization step through filtering during production.
The invention addresses the problem of providing a compound having Nrf2-activation action. The invention is the compound represented by general formula (I), a salt thereof, or a solvate thereof. General formula (I): In the formula: R1aand R1bare identical or different and represent a hydrogen atom, an alkyl group, or a halogen atom; R2represents an optionally substituted heterocycle-derived group, and the heterocycle represents thiophene, furan, pyrrole, or thiazole, or a condensed ring containing any of these heterocycles; R4and R5are identical or different and represent a hydrogen atom or an optionally substituted alkyl group, or R4and R5are bonded to one another to form -NH-CH=N-;R6represents an optionally substituted alkyl group; A1, A2, A3, and A4 are identical or different and represent CH or N (provided that there is at most one N); and Z represents a hydrogen atom or a halogen atom.
C07D 419/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote, d'oxygène et de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
A61K 31/554 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. clothiapine, diltiazem
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
The present disclosure provides a novel use of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). The present disclosure provides a composition that includes nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) for treating or preventing diseases, disorders, or symptoms related to activation of Hsd3b6 or a homolog thereof, and a method using the composition. In one embodiment, a composition including NMN or NR for improving the function of meibomian glands, and a method using the composition are provided.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
The purpose of the present invention is to provide a PACAP peptide having improved stability. The present invention is based on the finding that the stability of PACAP is significantly improved by substituting aspartic acid at positions 3 and 8 in the sequence of PACAP with at least one amino acid selected from the group consisting of tetrazole-substituted aspartic acid (Tz), tetrazole-substituted glutamic acid (egTz), tetrazole-substituted homoglutamic acid (nvTz), sulfoxy-substituted aspartic acid (cya), and oxadiazolone-substituted aspartic acid (5Oxa).
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
66.
COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS WHICH CONTAINS PACAP PEPTIDE OR STABILIZED PACAP PEPTIDE
The purpose of the present invention is to provide a composition for preventing or treating neurotrophic keratitis. It is found that PACAP peptide exerts an effect to prevent corneal damages in a neurotrophic keratitis model and can promote neurite extension in a cultured nerve cell model. Furthermore, stability can be significantly increased by substituting a carboxyl group in an aspartic acid residue located at position-3 and/or position-8 in the sequence for PACAP by tetrazole. Provided are: a composition for preventing or treating neurotrophic keratitis, which contains PACAP peptide or stabilized PACAP peptide; and a neurite extension promoting agent.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
The purpose of the present invention is to provide a PACAP peptide having increased stability. The problem is solved by the discovery that substituting a carboxy group of the position 3 and/or position 8 aspartic acid in the PACAP sequence by tetrazole significantly enhances stability.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/00 - Préparations médicinales contenant des peptides
The present disclosure provides a marker that shows a relationship with changes in the nerve density and shape in the cornea. In one aspect, the present invention provides a marker of neuropathy in the eye, the expression of which changes in correlation with morphological parameters of the nerves in the eye. In some embodiments, the parameter may include at least one parameter selected from the group consisting of CNBD, CTBD, CNFD, CNFL, and tortuosity. In a particular embodiment, the parameter may include at least one parameter selected from CNBD and CTBD.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
69.
COMBINED DRUG FOR TREATING OR PREVENTING RETINAL DISEASE ASSOCIATED WITH ANGIOGENESIS
The purpose of the preset invention is to provide a drug, which is useful for treating or preventing a retinal disease associated with angiogenesis and contributes to excellent medication compliance, or a combination therapy. The present invention pertains to a drug for treating or preventing a retinal disease associated with angiogenesis, said drug comprising a combination of (2S)-[4-(carboxymethyl)thiazol-2-ylthio]-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide or a pharmaceutically acceptable salt thereof with an anti-VEGF agent, and a combination therapy and a kit therefor.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
Provided is a stable aqueous formulation containing EPC-K. Also provided is a stablization method for the aqueous formulation containing the EPC-K. The aqueous formulation contains (a) dl-α-tocopherol-2-L-ascorbic acid phosphoric acid diester potassium salt and (b) at least one selected from the group consisting of polyoxyethylene alkyl phenyl ether, polyoxyethylene alkyl ether, and polyoxyethylene fatty acid ester. Moreover, the stabilization method for the aqueous formulation includes a step for preparing the aqueous formulation containing (a) dl-α-tocopherol-2-L-ascorbic acid phosphoric acid diester potassium salt and (b) at least one selected from the group consisting of polyoxyethylene alkyl phenyl ether, polyoxyethylene alkyl ether, and polyoxyethylene fatty acid ester.
A peptide fragment isolated from proline-rich protein 4 (PRP4) has a neuroprotective action. The peptide can be a neuroprotective drug in a preventive or alleviative pharmaceutical composition. The peptide can be used in a neuropathic treatment.
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 38/00 - Préparations médicinales contenant des peptides
NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT (Japon)
SENJU PHARMACEUTICAL CO., LTD. (Japon)
Inventeur(s)
Azuma, Noriyuki
Tanaka, Taku
Yokoi, Tadashi
Abrégé
An object of the present invention is to provide a method of inducing pluripotent stem cells to differentiate into clinically applicable retinal ganglion cells.
The present invention provides a method for inducing pluripotent stem cells to differentiate into retinal ganglion cells that can be used for clinical application. Such method is a method for producing retinal ganglion cells with elongated axons comprising the following steps: (a) a step of inducing pluripotent stem cells to differentiate into retinal progenitor cells via floating culture; (b) a step of inducing the retinal progenitor cells obtained in step (a) to differentiate into retinal ganglion cells via floating culture; and (c) a step of allowing axons to elongate via adhesion culture of the retinal ganglion cells obtained in step (b).
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
The present invention pertains to: a retinal ganglion cell death inhibitor that contains a BMPR signal transduction inhibitor; a protection drug that is for retinal nerves and that contains a BMPR signal transduction inhibitor; and a pharmaceutical composition that uses these and that is for preventing or treating diseases associated with retinal ganglion cell death, such as glaucoma, diabetic retinopathy, and retinal vascular occlusion.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 31/4418 - Pyridines non condenséesLeurs dérivés hydrogénés ayant un carbocycle lié directement à l'hétérocycle, p. ex. cyproheptadine
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
The purpose of the present invention is to provide a formulation technique pertaining to an aqueous liquid formulation that contains a water-soluble polymer, and brimonidine and/or a salt thereof. An aqueous liquid formulation containing a water-soluble polymer, brimonidine and/or a salt thereof, and polyhexanide and/or a salt thereof can suppress decreases in viscosity over time, can also suppress decreases in the content of brimonidine and/or salt thereof over time, and can provide exceptional formulation stability.
A61K 47/30 - Composés macromoléculaires organiques ou inorganiques, p. ex. polyphosphates inorganiques
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
Provided are: emulsion eyedrops which have no concern with possible corneal injury induced by a nonionic surfactant, have excellent thermal stability and physical stability and can contain a sparingly water-soluble drug in an increased amount; and an emulsion eyedrops stabilization method. The emulsion eyedrops contain castor oil and poly(vinyl alcohol), wherein the concentration of castor oil is 5 to 20 w/v %, the concentration of poly(vinyl alcohol) is 2 to 7 w/v %, and the ratio of the weight of castor oil to the weight of poly(vinyl alcohol) is 1.2 to 5. The emulsion eyedrops stabilization method is characterized by preparing emulsion eyedrops containing castor oil and poly(vinyl alcohol), wherein the concentration of castor oil is 5 to 20 w/v %, the concentration of poly(vinyl alcohol) is 2 to 7 w/v %, and the ratio of the weight of castor oil to the weight of poly(vinyl alcohol) is 1.2 to 5.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
The purpose of the present invention is to provide a hydrogel that has better shape stability than the prior art not only after but also during the release of an encapsulated anionic drug, as well as an anionic drug-containing ophthalmic device in which the hydrogel is used. The foregoing is achieved by an anionic drug-containing ophthalmic device and the like that comprises: (1) an anionic drug; and (2) a copolymer. The copolymer comprises, as constituents: a cationic monomer comprising a condensate, or a salt thereof, of an aminoalkyl quaternary ammonium compound having a (meth)acrylic acid and a substituted or unsubstituted aralkyl group; and a monomer copolymerizable therewith.
A61F 9/007 - Procédés ou dispositifs pour la chirurgie de l'œil
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
A61L 27/16 - Matériaux macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
The purpose of the present invention is to provide a formulation technique that is related to an aqueous liquid agent containing chlorobutanol. According to the present invention, an aqueous liquid agent which contains chlorobutanol and brimonidine and/or a salt thereof is able to be suppressed in decrease of pH over time, thereby being able to achieve excellent formulation stability.
The content of dibutylhydroxytoluene which is blended as an antioxidant in an ophthalmic liquid agent decreases in the ophthalmic liquid agent due to the volatility, adsorbability and degradability thereof. The present invention provides an ophthalmic liquid agent which is suppressed in decrease of the dibutylhydroxytoluene content by blending dibutylhydroxytoluene together with at least one thickening agent that is selected from the group consisting of xanthane gum, gelatin and carrageenan.
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
The purpose of the present invention is to provide a technique for suppressing the generation of degradation products due to storage and improving the storage stability in an ophthalmic composition that contains brimonidine and/or a salt thereof, timolol and/or a salt thereof, and phosphoric acid and/or a salt thereof. The concentration of the phosphoric acid and/or salt thereof is set at 32 mM or less in the ophthalmic composition that contains brimonidine and/or a salt thereof, timolol and/or a salt thereof, and phosphoric acid and/or a salt thereof.
The present invention provides a means for treating and/or preventing peripheral nerve disorder by facilitating regeneration of peripheral nerves. Specifically, the present invention provides a composition for treating and/or preventing peripheral nerve disorder comprising a compound represented by the general formula (I):
3 is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.
A61K 31/27 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbamiques ou thiocarbamiques, p. ex. méprobamate, carbachol, néostigmine
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/341 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide non condensés avec un autre cycle, p. ex. ranitidine, furosémide, bufétolol, muscarine
A61K 31/351 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle non condensés avec un autre cycle
A61K 31/4402 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 2, p. ex. phéniramine, bisacodyl
The purpose of the present invention is to provide pharmaceutical technology that makes it possible to obtain at least preservation efficacy equal to or exceeding a level at which bacteriostatic action is observed in an aqueous liquid formulation containing brimonidine and/or a salt thereof without mixing preservatives into said aqueous liquid formulation. An aqueous liquid formulation containing brimonidine and/or a salt thereof, edetic acid and/or a salt thereof, and a buffer agent makes it possible to obtain at least preservation efficacy at a level at which bacteriostatic action is observed despite said aqueous liquid formulation containing substantially no preservatives.
The purpose of the present invention is to provide an aqueous liquid formulation that contains brimonidine and/or a salt thereof and that has excellent preservation efficacy despite containing substantially no preservatives. An aqueous liquid formulation containing brimonidine and/or a salt thereof, edetic acid and/or a salt thereof, and boric acid and/or a salt thereof makes it possible to obtain excellent preservation efficacy despite said aqueous liquid formulation containing substantially no preservatives.
The present disclosure provides a composition for treating or preventing symptoms, disorders, or diseases of the corneal endothelium. The present invention specifically provides a composition which is for treating or preventing symptoms, disorders, or diseases of the corneal endothelium, and includes (T)EW-7197 (N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), a derivative thereof, a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
Provided is a preparation technology whereby reduction in viscosity over time can be suppressed in an aqueous liquid agent containing a water-soluble polymer. This aqueous liquid agent containing a water-soluble polymer has either brimonidine and/or a salt thereof or chlorhexidine gluconate, or both, present therein.
A61K 47/16 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'azote
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
The purpose of the present invention is to provide a PACAP peptide having increased stability. The problem is solved by the discovery that substituting a carboxy group of the position 3 and/or position 8 aspartic acid in the PACAP sequence by tetrazole significantly enhances stability.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C12N 15/12 - Gènes codant pour des protéines animales
A peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing the peptide, and a preventive or alleviative pharmaceutical composition. The peptide comprises proline-rich protein 4 having the sequence of SEQ ID NO:1 or a partial sequence thereof, or a modified sequence thereof, which has a neuroprotective action.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 21/02 - Relaxants musculaires, p. ex. pour la tétanie ou les crampes
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
The present invention provides a squeeze container capable of reducing remaining contents without greatly compressing and deforming the vicinity of a shoulder portion thereof. The present invention relates to a squeeze container for discharging contents by compressing a body portion back and forth from the outside, wherein the body portion has a shape of a polygon or an oval tapered in a left-right direction in plan view, the body portion includes a pair of front-and-back pressing portions that is disposed to face each other so as to flatten the polygonal or the oval in the left-right direction by being compressed back and forth so as to be brought into close contact with each other, and a pair of left-and-right tapered portions connecting the pressing portions to each other, and a pair of front-and-back V-shaped grooves are provided between each of the pressing portions of the body portion and the shoulder portion so as to face each other while being recessed in a central axis direction of the body portion and having a groove bottom formed by an upper bending line extending substantially horizontally.
The purpose of the present invention is to provide a technique for formulating a two-layer separation-type ophthalmic solution in which, during storage, an aqueous layer and an oil-containing layer containing squalane are separated from each other, wherein it is possible to homogeneously disperse the oil-containing layer in the aqueous layer while suppressing foaming by shaking the ophthalmic solution before administration, and the homogeneous dispersed state is maintained in a stable manner at least until administration. A two-layer separation-type ophthalmic solution containing squalane and water, wherein hyaluronic acid and/or a salt thereof and polyvinyl alcohol are contained in the ophthalmic solution and the polyvinyl alcohol content is set to 0.025 to 0.1 w/v %, whereby it is possible to homogeneously disperse the oil-containing layer in the aqueous layer while suppressing foaming by shaking the ophthalmic solution before administration, and to maintain the homogeneous dispersed state in a stable manner at least until administration.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
Provided are: emulsion eyedrops by which there is no possibility of a corneal disorder occurring due to a nonionic surfactant, that are excellent in terms of thermal stability and physical stability, and that can contain a higher content of a sparingly water-soluble drug; and a stabilization method for emulsion eyedrops. The emulsion eyedrops contain castor oil and polyvinyl alcohol and have a castor oil concentration of 5-20 w/v% and a polyvinyl alcohol concentration of 2-7 w/v%, the ratio of the weight of the castor oil to the weight of the polyvinyl alcohol being 1.2-5. The stabilization method for emulsion eyedrops is characterized by preparing emulsion eyedrops which contain castor oil and polyvinyl alcohol and have a castor oil concentration of 5-20 w/v% and a polyvinyl alcohol concentration of 2-7 w/v%, the ratio of the weight of the castor oil to the weight of the polyvinyl alcohol being 1.2-5.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
35 - Publicité; Affaires commerciales
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Chemicals; glue and adhesives for industrial purposes; plant
growth regulating preparations; chemical additives for use
as ingredients in cosmetics. Soaps and detergents; cosmetics; ingredients containing
diester compound of maleic acid formed with tocopherol and
ascorbic acid, sold as a component of cosmetics, namely
creams and lotions. Pharmaceutical preparations for ophthalmic use; eye drops;
contact lens cleaning preparations; solutions for contact
lenses; pharmaceutical, veterinary and sanitary preparations
for medical purposes; oiled paper for medical purposes;
cachets for pharmaceutical purposes; gauze for dressings;
empty capsules for pharmaceuticals; eye patches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary napkins; sanitary panties; absorbent
cotton; adhesive plasters; bandages for dressings; liquid
dressings; breast-nursing pads; dental materials. Finger guards for medical purposes; pacifiers for babies;
ice bag pillows for medical purposes; triangular bandages;
supportive bandages; surgical catguts; feeding cups for
medical purposes; dropping pipettes for medical purposes;
teats; medical ice bags; medical ice bag holders; baby
bottles; nursing bottles; diagnostic apparatus and
instruments; surgical apparatus and instruments; therapeutic
apparatus and instruments; medical apparatus and
instruments; veterinary apparatus and instruments; auxiliary
medical devices and orthodontic apparatus; sanitary masks. Advertising and publicity services; business management
analysis or business consultancy; marketing research or
analysis; providing information concerning commercial sales;
employment agencies; retail services or wholesale services
for pharmaceutical, veterinary and sanitary preparations and
medical supplies; retail services or wholesale services for
cosmetics, toiletries, dentifrices, soaps and detergents. Medical practice; providing medical information; physical
examination; dentistry services; preparation and dispensing
of medications; animal breeding; veterinary services;
beautification for animals; rental of medical apparatus and
instruments.
92.
Agent for prevention or treatement of corneal disorders
An object of the invention is to provide an agent for preventing or treating corneal disorders, such as corneal epithelial disorder, dry eye, and reduction in corneal sensitivity. This object is achieved by using angiopoietin-like protein 7 as an active ingredient.
A61K 38/00 - Préparations médicinales contenant des peptides
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
Provided is an Fc fusion high affinity IgE receptor α-chain having excellent stability at low pH.
a linker fragment region between the (i) and the (ii) is the amino acid sequence shown in SEQ ID NO: 2.
The purpose of the present invention is to provide an ophthalmic pharmaceutical product which, while an ophthalmic solution containing brimonidine and/or a salt thereof, brinzolamide and/or a salt thereof, a carboxyvinyl polymer, and a dihydric alcohol and/or a trihydric alcohol is stored in a storing body that allows visual recognition of the inside thereof, enables suppression of increase in the viscosity of the ophthalmic solution due to exposure thereof to light. According to the present invention, an ophthalmic solution containing brimonidine and/or a salt thereof, brinzolamide and/or a salt thereof, a carboxyvinyl polymer, and a dihydric alcohol and/or a trihydric alcohol is stored in a transparent storing body in which the maximum transmittance of light having a wavelength of 360-460 nm is not higher than 67% and in which the maximum transmittance of light having a wavelength of 600-680 nm is not higher than 78%, whereby, while an insoluble foreign matter test and visual recognition of the amount of a residual liquid are enabled, increase in the viscosity due to exposure to light can be suppressed, thereby ensuring formulation stability.
A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinoxaline, phénazine
A61K 31/542 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes hétérocycliques
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
Provided is a means for treating and/or preventing a peripheral nerve disorder through promotion of regeneration of peripheral nerves. More specifically, provided is a composition for treatment and/or prevention of a peripheral nerve disorder that contains the compound represented by formula (I) (wherein: R1 represents a lower alkyl group substituted by a lower alkoxy group, a lower alkyl group substituted by a heterocyclic group, a heterocyclic group, or a group represented by formula (IIa) (wherein, R4 represents a lower alkyl group, R5 represents a lower alkylene group, and m represents an integer of 1-6); R2 represents a lower alkyl group optionally substituted by a phenyl group; and R3 represents a lower alkyl group (optionally substituted by a halogen, a lower alkoxy group, or a phenyl group), a condensed polycyclic hydrocarbon group, or a hydrogen atom).
A61K 31/27 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbamiques ou thiocarbamiques, p. ex. méprobamate, carbachol, néostigmine
A61K 31/341 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide non condensés avec un autre cycle, p. ex. ranitidine, furosémide, bufétolol, muscarine
A61K 31/351 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle non condensés avec un autre cycle
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 31/4402 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 2, p. ex. phéniramine, bisacodyl
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japon)
THE DOSHISHA (Japon)
SENJU PHARMACEUTICAL CO., LTD. (Japon)
Inventeur(s)
Koizumi, Noriko
Okumura, Naoki
Kinoshita, Shigeru
Abrégé
The present invention provides a technique for treating retinal epithelium and/or nerves. More specifically, the present invention is an agent for the treatment or prevention of retinal disease or the like and/or a disease, disorder, or ophthalmological state of the nerves, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with retinal pigment epithelial cells and/or nerve cells. Specifically, the present invention can include laminin 411 (α4β1γ1), laminin 511 (α5β1γ1), laminin 521 (α5β2γ1), or fragments of these.
FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (Espagne)
SENJU PHARMACEUTICAL CO., LTD. (Japon)
Inventeur(s)
García Dorado García, Antonio David
Inserte Igual, Javier
Poncelas Nozal, Marcos
Abrégé
The present invention relates to calpain inhibitors for use in the prevention and/or treatment of adverse ventricular remodelling. In particular, they are for use in the adverse ventricular remodelling accompanying a myocardial infarction or due to chronic hypertension. The invention also relates to particular compositions comprising these inhibitors.
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japon)
THE DOSHISHA (Japon)
SENJU PHARMACEUTICAL CO., LTD. (Japon)
Inventeur(s)
Koizumi, Noriko
Okumura, Naoki
Kinoshita, Shigeru
Abrégé
The present invention provides a technique for treating the cornea. More specifically, the present invention is an agent for the treatment or prevention of a state of corneal endothelial disease, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with corneal endothelial cells. Specifically, the present invention can include laminin 511 (α5β1γ1), laminin 521 (α5β2γ1), or a fragment of these.
The purpose of the present invention is to provide a formulation technique whereby it becomes possible to maintain glycyl-L-arginylglycyl-3-sulfo-L-alanyl-L-threonyl-L-proline and/or a salt thereof stably in an aqueous liquid agent containing glycyl-L-arginylglycyl-3-sulfo-L-alanyl-L-threonyl-L-proline and/or the salt thereof to impart excellent storage stability to the aqueous liquid agent. Citric acid and/or a salt thereof is added in an amount of 0.0005 to 0.015 w/v% in terms of a free acid content to an aqueous liquid agent containing glycyl-L-arginylglycyl-3-sulfo-L-alanyl-L-threonyl-L-proline and/or a salt thereof, and the pH value of the aqueous liquid agent is adjusted to 3.5 to 4.5. In this manner, the decomposition of glycyl-L-arginylglycyl-3-sulfo-L-alanyl-L-threonyl-L-proline and/or the salt thereof over time can be prevented effectively, and therefore excellent storage stability can be imparted to the aqueous liquid agent.
The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This is based on the finding that a peptide fragment isolated from proline-rich protein 4 (PRP4) has a neuroprotective action.
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 21/02 - Relaxants musculaires, p. ex. pour la tétanie ou les crampes
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07K 5/117 - Tétrapeptides le premier amino-acide étant hétérocyclique, p. ex. Pro, His, Trp
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
